Literature DB >> 2452738

Acute-phase proteins in Alzheimer's disease.

B Giometto1, V Argentiero, F Sanson, G Ongaro, B Tavolato.   

Abstract

The main 'acute-phase proteins' were determined in serum of 20 patients with presenile Alzheimer's disease (AD) and compared with values in 18 age-matched healthy control subjects. Following parameters were evaluated: alpha 1-antitrypsin (alpha AT), haptoglobin (HPT), transferrin (TRF), acidic alpha 1-glycoprotein (A alpha G), ceruloplasmin (CER), alpha 2-macroglobulin (alpha MG), C-reactive protein (CRP), albumin (ALB), together with the immunoglobulins IgG, IgM and IgA, and some of the most significant factors of the classic (C3, C4) and alternative (properdin factor B) pathways of complement activation. The results showed a statistically significant increase in the levels of alpha AT (p less than 0.001), CER (p less than 0.001) and of all the complement factors studied (p less than 0.005). The levels of other acute-phase protein (HPT, TRF, A alpha G, alpha MG, CRP, ALB) and immunoglobulins (IgG, IgM, IgA) were similar in AD patients and normal controls. These results give rise the possibility that these elements indicate an altered immunoregulation compatible with chronic cell damage and/or chronic inflammation conditions. Moreover, the increased level of alpha AT can be related to the low production of interleukin-1 (IL-1) reported in AD, which supports the hypothesis of a relative derangement of the macrophage function in presenile AD patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452738     DOI: 10.1159/000116224

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  10 in total

1.  Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Authors:  Steven P Millard; Franziska Lutz; Ge Li; Douglas R Galasko; Martin R Farlow; Joseph F Quinn; Jeffrey A Kaye; James B Leverenz; Debby Tsuang; Chang-En Yu; Elaine R Peskind; Lynn M Bekris
Journal:  Neurobiol Aging       Date:  2013-09-04       Impact factor: 4.673

2.  Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study.

Authors:  Matthew Zabel; Matthew Schrag; Claudius Mueller; Weidong Zhou; Andrew Crofton; Floyd Petersen; April Dickson; Wolff M Kirsch
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  The roles of neutral sphingomyelinases in neurological pathologies.

Authors:  Charles R Horres; Yusuf A Hannun
Journal:  Neurochem Res       Date:  2012-01-12       Impact factor: 3.996

4.  Alpha 1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha 1-antichymotrypsin immunostaining in the Alzheimer brain.

Authors:  M Shoji; S Hirai; H Yamaguchi; Y Harigaya; K Ishiguro; E Matsubara
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

5.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

6.  Serum alpha 1-antitrypsin and alpha 2-macroglobulin in Alzheimer's and Binswanger's disease.

Authors:  T Wetterling; K F Tegtmeyer
Journal:  Clin Investig       Date:  1994-02

7.  Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology.

Authors:  Ibrahima Diouf; Ashley I Bush; Scott Ayton
Journal:  Neurobiol Dis       Date:  2020-02-19       Impact factor: 5.996

8.  Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS).

Authors:  Janette Bester; Prashilla Soma; Douglas B Kell; Etheresia Pretorius
Journal:  Oncotarget       Date:  2015-11-03

9.  CCAAT-enhancer binding protein-β expression and elevation in Alzheimer's disease and microglial cell cultures.

Authors:  Ron Strohmeyer; Jadd Shelton; Christopher Lougheed; Trisia Breitkopf
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

10.  Plasma lipoproteome in Alzheimer's disease: a proof-of-concept study.

Authors:  Ling Li; Fang Yu; Danni Li; Fangying Huang; Yingchun Zhao; Peter W Villata; Timothy J Griffin; Lin Zhang
Journal:  Clin Proteomics       Date:  2018-09-20       Impact factor: 3.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.